Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07772895 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pemefolacianine for IMI of Lung Cancer

Name: Pemefolacianine for IMI of Lung Cancer — clinical trial record (NCT07772895)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorSunil Singhal

Started2026-03-11

View on ClinicalTrials.gov ↗

The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of Pemefolacianine for Injection, a novel fluorescence imaging agent developed by Nanjing Nuoyuan Medical Devices Co., Ltd (Nuoyuan Medical), administered by slow intravenous (IV) in patients undergoing surgical thoracoscopy and/or RATS (Robot-Assisted Thoracoscopic Surgery) resection of lung cancer. Safety is the primary objective of this study, followed by evaluation of the fluorescence signal as it relates to dose level and dosing time interval which will not be used for decision-making in the surgical resection in this study.

Trial Details

NCT Number	NCT07772895
Lead Sponsor	Sunil Singhal
Conditions	Lung Cancer (Locally Advanced or Metastatic)
Enrollment	12 participants
Start Date	2026-03-11
Primary Completion	2027-03-11 (estimated)
Study Completion	2027-03-11 (estimated)
Updated on ClinicalTrials.gov	2026-08-19